95 filings
8-K
SKYE
Skye Bioscience Inc
10 Jun 24
Skye Concentrates Strategy and Clinical Development Focus on Nimacimab Metabolic Program
9:27am
8-K
SKYE
Skye Bioscience Inc
3 Apr 24
Regulation FD Disclosure
5:07pm
8-K
SKYE
Skye Bioscience Inc
13 Mar 24
Entry into a Material Definitive Agreement
4:13pm
8-K
SKYE
Skye Bioscience Inc
4 Mar 24
Skye Bioscience Appoints Dr. Annalisa Jenkins to Board of Directors
4:23pm
8-K
SKYE
Skye Bioscience Inc
12 Feb 24
Other Events
4:18pm
8-K
anyg8pl0geytx
29 Jan 24
Skye Bioscience Announces $50.25 Million Private Placement Equity Financing
8:02am
8-K
jx0a6kb1a3of5di63108
5 Dec 23
Entry into a Material Definitive Agreement
5:04pm
8-K
r4l5xo x84r
6 Nov 23
Amendments to Articles of Incorporation or Bylaws
8:21pm
8-K
2f9t0yy6ju5
3 Oct 23
Departure of Directors or Certain Officers
4:34pm
8-K
noekhl6ge ktrax319
7 Sep 23
Skye Bioscience Reverse Stock Split to be Effective on September 8th
1:15pm
8-K/A
vgrhvtbur3q
1 Sep 23
Departure of Directors or Certain Officers
12:00am
8-K
vc0vw 54o3
21 Aug 23
Skye Completes $17M Financing and Acquires Novel Phase 2-Ready CB1-Inhibiting Monoclonal Antibody
8:36am
8-K/A
qxcuwm ww
27 Mar 23
Departure of Directors or Certain Officers
4:09pm
8-K
psxryt49iq0aiori 45b
23 Feb 23
Entry into a Material Definitive Agreement
5:18pm
8-K
9yh7h7l p8v5hm
16 Feb 23
Skye Bioscience Appoints Deborah Charych, PhD to Board of Directors
5:16pm
8-K
24d3bhse dyn
15 Feb 23
Skye Bioscience Closes Sale of Subsidiary, Verdélite Sciences, to C3 Souvenir Holding, with USD$5.60M Closing Payment
4:26pm
8-K
ntb81ugj3g7
26 Jan 23
Entry into a Material Definitive Agreement
9:22pm
8-K
8e0d2
6 Jan 23
Entry into a Material Definitive Agreement
4:57pm
8-K
6zlqfs57i3wfy a481
16 Dec 22
Entry into a Material Definitive Agreement
6:40pm
8-K
cfbqee101f64cb95e9hb
23 Nov 22
Entry into a Material Definitive Agreement
5:23pm